← Back to headlines
US approves groundbreaking pancreatic cancer drug that doubles survival rates
The newly authorized treatment has shown remarkable efficacy in clinical trials, effectively doubling survival times for patients and earning standing ovations at oncology conferences.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
